ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

Published Date: 21 Oct 2026

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

Read Full News

Latest News

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

Todays Updates

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study Louie Pasculli

Ocrelizumab demonstrated noninferiority to fingolimod for relapse control but displayed greater reductions in MRI lesion activity among pediatric patients with relapsing-remitting multiple sclerosis.

Todays Updates

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study Louie Pasculli

Ocrelizumab demonstrated noninferiority to fingolimod for relapse control but displayed greater reductions in MRI lesion activity among pediatric patients with relapsing-remitting multiple sclerosis.

Latest News

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

News All Time

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Insurance Formularies Holding Up Lower-Emission Asthma, COPD Inhalers

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

Lung Cancer Diagnosis Linked to Lung Microplastic Presence, Quantity Victoria Johnson

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Childhood Pollution Exposure May Trigger COPD Polygenic Risk Victoria Johnson

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

7 Pulmonology Headlines You Missed in August 2026 Victoria Johnson

August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.

Q&A: PERFORM Data Support Triple Therapy in Milder Uncontrolled Asthma John Oppenheimer, MD

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

Zumilokibart Rapidly Suppresses FeNO in Phase 1b Asthma Data: Mario Castro, MD Mario Castro, MD, MPH

Castro, of University of Kansas discusses interim phase 1b data showing rapid, durable suppression in patients with mild to moderate asthma.

GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF Victoria Johnson

The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

Latest News

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

Todays Updates

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study Louie Pasculli

Todays Updates

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study Louie Pasculli

Latest News

News All Time

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Insurance Formularies Holding Up Lower-Emission Asthma, COPD Inhalers

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Lung Cancer Diagnosis Linked to Lung Microplastic Presence, Quantity Victoria Johnson

Childhood Pollution Exposure May Trigger COPD Polygenic Risk Victoria Johnson

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

7 Pulmonology Headlines You Missed in August 2026 Victoria Johnson

Q&A: PERFORM Data Support Triple Therapy in Milder Uncontrolled Asthma John Oppenheimer, MD

Zumilokibart Rapidly Suppresses FeNO in Phase 1b Asthma Data: Mario Castro, MD Mario Castro, MD, MPH

GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF Victoria Johnson

Recommended News For You

Is Vitamin D a Key to Better Breast Cancer Survival?

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

Breast cancer: A new target to eliminate dormant cells before they wake

Many Americans unaware of links between HPV and cancers, poll reveals

Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

Recommended Articles For You

A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Prognostic Patterns of Functional Recovery During Long-Term Cancer Survivorship

The Importance of Having a Quick and Effective Heparin Antidote

Hematopoietic Immune Microenvironment Plasticity: Mechanisms, Clinical Implications, and Emerging Therapeutics

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.